Biocomparable medicines are currently among the hottest topics in regard to life sciences legislation in Mexico. Daniel Sánchez and Victor Ramirez investigate.
Biological drugs and the legislation and regulation surrounding them are topics that have provided more than one headache to governments around the world. If the fight between innovators and generic companies over non-biological medicines has always been more a matter of industrial property, when a biological medicine is involved, regulatory concerns increase the complexity of the debate.
Biological medicines cannot be treated in the same way as non-biological medicines by the domestic health authorities, because the usual standards for safety, efficacy and quality are not suitable for proving that one particular biological medicine is a generic version of another, previously authorised one.
With these problems in mind, each country has been developing its own legislation. In some cases, domestic governments may follow what other countries are doing (the US, the EU, etc), but in the case of Mexico, the government, through the Ministry of Health and COFEPRIS (the department in charge of granting marketing authorisations for new drugs) has chosen the following solution.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
biologics, biocomparables, Mexico, COFEPRIS, generics